Showing 20,121 - 20,140 results of 105,995 for search '(( a fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.87s Refine Results
  1. 20121

    A bis-sulphamoylated estradiol derivative induces ROS-dependent cell cycle abnormalities and subsequent apoptosis by Michelle Helen Visagie (3927308)

    Published 2017
    “…Our data shows that EMBS targets a pathway that leads to increased ROS production as an early event that culminates in G<sub>2</sub>/M arrest and apoptosis by means of JNK-signaling in cancer cells. …”
  2. 20122

    Induction of interferon-responsive genes. by Jian Chen (15340)

    Published 2015
    “…<i>IFI6</i> and <i>STAT1</i> increased with treatment, while <i>STAT3</i> decreased. Fold changes were calculated as described in the methods section. …”
  3. 20123
  4. 20124
  5. 20125
  6. 20126
  7. 20127
  8. 20128
  9. 20129
  10. 20130
  11. 20131

    Bedload composition, transport and modification in rivers of Westland, New Zealand, with implications for the distribution of alluvial pounamu (jade) by SC Cox (740448)

    Published 2015
    “…Arahura has greater total concentrations (10<sup>3</sup>–10<sup>5</sup> t/km<sup>2</sup>) and proportions (5–40%) of ultramafic bedload compared with Hokitika and Taramakau catchments (10<sup>1</sup>–10<sup>4</sup> t/km<sup>2</sup>, mostly <10%), matching relative areas of mapped Pounamu Ultramafic bedrock, but enriched relative to absolute areal proportions. …”
  12. 20132
  13. 20133
  14. 20134

    DataSheet_1_OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.docx by Charlotte Primard (1929874)

    Published 2023
    “…<p>Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM<sup>®</sup>, a self-assembling domain which improves antigen immunogenicity. …”
  15. 20135

    Effects of AP-5 application on EPSCs in control and hyperglycemic mice. by Eva C. Bach (709723)

    Published 2015
    “…<b>D.</b> Mean percent decrease in mEPSC frequency following application of AP-5 in control (n = 9) and hyperglycemic (n = 10) mice. …”
  16. 20136

    CRISPRi knockdown of Lon protease to increase half-life. by Nicholas A. Rossi (3622865)

    Published 2018
    “…Bivariate scatter plots show P<sub><i>inaA</i></sub> and P<sub><i>acrAB</i></sub> expression levels at the final time point across n = 5 microcolonies. …”
  17. 20137

    Performance of the intact model. by Yaroslav I. Molkov (542831)

    Published 2015
    “…At lower values of <i>α</i> two distinct regimes exist: the first has a phase difference between flexor centers less than 0.5 (lower branch) which corresponds to the activation pattern shown in <b>A</b> (LF leads, RF activates on LF’s shutdown, then a pause until LF activates again) and the second regime has a phase difference greater than 0.5 (upper branch) when RF activates first and LF activates on RF’s shutdown (not shown on <b>A</b>). …”
  18. 20138

    Image 2_Huashi Runzao decoction for primary Sjögren disease: a double-blind, randomized controlled trial combined with m6A and m5C RNA modification analysis.tif by Ziwei Huang (192096)

    Published 2025
    “…Moreover, HRD increased m6A levels and decreased m5C levels in pSD patients, and HNRNPA2B1 was identified as a potential key epigenetic regulator.…”
  19. 20139

    Image 1_Huashi Runzao decoction for primary Sjögren disease: a double-blind, randomized controlled trial combined with m6A and m5C RNA modification analysis.tif by Ziwei Huang (192096)

    Published 2025
    “…Moreover, HRD increased m6A levels and decreased m5C levels in pSD patients, and HNRNPA2B1 was identified as a potential key epigenetic regulator.…”
  20. 20140